Novartis To Get Hold Of Fougera For $1.5 Billion For Skin Medications
Thu, 05/03/2012 - 07:11 | 
Swiss pharma giant Novartis stated that it is purchasing dermatology generics firm Fougera for around $1.525 billion, a move that would propel the group to market head spot on generic dermatology medications.
Watson Pharmaceuticals first-quarter income surged 22% as the drug manufacturer announced sharply higher income with a boost from novel generic medications and as its branded pharmaceuticals and distribution biz also registered double-digit growth.
Endo Pharmaceuticals posted a first-quarter loss after assimilating a $110-million pre-tax charge linked to a settlement and license agreement with Impax Laboratories Inc.
Tags: Novartis Recalls Excedrin; Endo Pharma Inks Licensing Deal With BioDelivery
Swiss pharma giant Novartis stated that it was recalling four different medications sold over the counter in the US market following reports of a malfunction at one of its facilities.
Synta Pharmaceuticals is offering 7 million scrips of common stock to the public, with the prospective of making net income of $28.6 million, the company said.
Savient Pharmaceuticals declared that a product-specific billing system, or lasting J-code, for KRYSTEXXA® (pegloticase) became accessible on January 1, 2012.
Endo Pharmaceuticals has decided to pay around $180 million for licensing rights
